InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company also develops INF904, an oral, small molecule drug candidate for the undisclosed chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

InflaRx N.V.

InflaRx is a biopharmaceutical company developing therapeutics targeting the C5a/C5aR signaling axis of the complement system. InflaRx focuses on diseases with high unmet medical need, developing treatments for inflammatory diseases, oncology, and critically ill COVID-19 patients.

InflaRx

InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx’s lead product candidate, vilobelimab, is a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies in different indications. InflaRx is also developing INF904, an orally administered, small molecule inhibitor of the C5a receptor. InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit www.inflarx.com

German Federal Ministry of Education and Research (BMBF)

Federal Ministry of Health

Shutai Shen (Beijing) Biopharmaceutical

bm-t beteiligungsmanagement thuringen

Affentranger Associates

Staidson Hongkong Investment

Bain Capital Life Sciences

Cormorant Asset Management

RA Capital Management

Today, we announced that we will report our second quarter 2024 financial and operating results on August 8, 2024, before the market opens.

For more news on InflaRx events, please visit our website: https://lnkd.in/eHz-MqMN

We are excited to present new preclinical data for our novel oral C5aR inhibitor #INF904 at the 2024 European Meeting on Complement in Human Diseases (EMCHD), which will be held in Lübeck, Germany, September 2 – 6, 2024.  
 
In addition to two poster presentations, InflaRx representatives will participate in a C5a/C5aR-focused panel discussion as well as speak at a satellite symposium. EMCHD 2024 focuses on translating scientific advancements in the complement field to new therapies for human diseases. 
 
More information can be found here: https://lnkd.in/d7UPBUXX

Our CSO and Co-Founder Renfeng Guo gave a presentation, “Inhibition of the C5a/C5aR1 Pathway: Controlling Inflammation from Bench to Bedside”, at the 16th World Congress on Inflammation (#WCI) on July 23rd.

#C5a is one of the most potent pro-inflammatory peptides, playing a crucial role in the pathogenesis of numerous inflammatory disorders. #Vilobelimab, a C5a inhibitor, has demonstrated life-saving potential in a Phase 3 study (PANAMO) in severe COVID-19 and is in late-stage clinical development for pyoderma gangrenosum, a severe inflammatory skin condition.

Click through the slides below to learn more about vilobelimab’s mode of action in controlling inflammation.

We are excited to announce that #GOHIBIC (vilobelimab) has been selected by Biomedical Advanced Research and Development Authority (BARDA) as an investigational therapy to be assessed in a Phase 2 clinical platform study that explores potential new options for the treatment of #ARDS. 

The Phase 2 multicenter, randomized, double-blind, placebo-controlled trial, will evaluate the safety and efficacy of three selected novel host-directed therapeutics, including GOHIBIC, at approximately 60 U.S. sites, with a total target enrollment of 600 hospitalized adults with ARDS. Given vilobelimab’s potent inhibition of #C5a and a host-directed mechanism of action, we believe it has the potential for broader applicability as a potent anti-inflammatory agent in ARDS.

Read the full press release here: https://lnkd.in/dSihN_yt

We are excited that JAMA Dermatology has published a case report titled, “Treatment of Pyoderma Gangrenosum With Vilobelimab” from our completed Phase 2 trial in pyoderma gangrenosum (PG).

PG is a rare neutrophilic dermatosis that often results in significant morbidity due to rapidly progressing cutaneous ulcerations. There are no FDA-approved medications for PG and patients are often treated with different immunomodulators including corticosteroids and biologics. Vilobelimab’s mode of action is highly relevant to PG, as it targets C5a, a strong activator of neutrophils.

The case report discusses the treatment of a patient suffering from this debilitating inflammatory condition with #vilobelimab, InflaRx’s anti-complement factor #C5a monoclonal antibody. A PG ulcer that had been present for 6 months prior to inclusion in the study showed complete closure by Day 71 during vilobelimab treatment and did not relapse during the observation time after discontinuation of vilobelimab. Concurrent treatment with other immunomodulation was well tolerated by this patient.
This further underscores vilobelimab’s potential for treating neutrophil-driven disorders such as PG and other conditions. 

You can find the full article in JAMA here: https://lnkd.in/dvfgnXvY 

InflaRx is currently conducting a Phase 3 trial investigating the efficacy and safety of vilobelimab in patients with ulcerative PG, with an interim analysis expected in 2025.

More and more, experts are turning to C5a as potent mediator of inflammation. With #vilobelimab and #INF904 we have two distinct ways to tackle the C5a/C5aR signaling cascade. Our CSO Renfeng Guo presentimg about this exciting topic this week!

	Dec '15	Dec '16	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
asset turnover			0.00 -						0.00 -
cash conversion cycle									25.21K -
cash per share	0.14 -	1.24 781.80%	13.10 953.32%	6.24 52.37%	4.44 28.82%	3.00 32.50%	2.00 33.16%	1.85 7.64%	1.64 11.14%
company equity multiplier	-0.20 -	-1.15 464.56%	1.04 190.51%	1.05 1.12%	1.13 7.89%	1.13 0.15%	1.19 4.91%	1.16 2.49%	1.17 1.10%
days of inventory outstanding									4.08K -
days of payables outstanding									1.83K -
days of sales outstanding			189.61 -						22.97K -
dividend yield
ebit per revenue			-84.18 -						-921.30 -
ebt per ebit	1.30 -	1.30 0.22%	1.25 3.91%	0.79 36.24%	0.94 18.05%	1.00 6.73%	0.96 4.32%	0.91 4.52%	0.73 19.74%
effective tax rate	-0.24 -	-0.21 15.13%	-0.09 55.23%	-0.26 180.91%	0.07 125.54%	-0.00 101.16%	-0.00 29.05%	0.08 15,360.30%	-0.00 100.00%
enterprise value multiple	-83.71 -	-42.88 48.77%	-1.79 95.83%	-17.27 866.61%	-1.05 93.92%	-2.66 153.57%	-3.20 20.24%	-3.63 13.26%	-1.23 66.07%
fixed asset turnover			1.34 -						0.05 -
free cash flow per share	-0.14 -	-0.22 51.94%	-1.31 506.46%	-0.98 25.26%	-1.68 72.39%	-1.35 19.66%	-0.96 29.04%	-0.77 20.13%	-0.68 11.91%
gross profit margin			1 -						-15.49 -
interest coverage	-3.58 -	-3.75 4.80%	-8.72 132.43%			-1.31K -	-1.92K 47.31%	-712.44 62.95%	-1.63K 128.99%
inventory turnover									0.09 -
long term debt to capitalization					0.00 -	0.00 8.23%	0.01 255.04%	0.01 10.22%
net income per ebt	1 -	1 0%	1 0%	1.00 0.00%	0.93 6.60%	1.00 7.15%	1.00 0.02%	0.92 8.33%	1 9.03%
net profit margin			-104.93 -						-676.32 -
operating cash flow per share	-0.14 -	-0.21 50.94%	-1.29 505.47%	-0.94 26.83%	-1.66 75.83%	-1.35 18.77%	-0.96 28.92%	-0.76 20.44%	-0.67 11.68%
operating cycle									27.04K -
operating profit margin			-84.18 -						-921.30 -
payables turnover									0.20 -
pretax profit margin			-104.93 -						-676.32 -
price fair value	-18.34 -	-12.93 29.52%	1.33 110.25%	5.27 297.42%	0.86 83.71%	1.44 67.44%	1.66 15.68%	1.45 12.59%	0.79 45.68%
receivables turnover			1.93 -						0.02 -
return on assets	-1.37 -	-0.30 77.91%	-0.20 35.56%	-0.19 4.03%	-0.41 118.48%	-0.39 5.77%	-0.36 5.37%	-0.26 27.61%	-0.35 31.54%
return on capital employed	-1.20 -	-0.25 79.33%	-0.16 34.39%	-0.25 52.16%	-0.53 113.16%	-0.43 17.71%	-0.45 3.05%	-0.36 19.44%	-0.55 52.57%
return on equity	0.28 -	0.35 24.69%	-0.20 158.32%	-0.20 2.96%	-0.46 135.72%	-0.44 5.91%	-0.43 0.72%	-0.31 29.42%	-0.41 32.99%
total debt to capitalization			0.00 -		0.01 -	0.01 9.00%	0.01 88.31%	0.02 12.66%	0.00 75.96%

DE:INFLARX

InflaRx

Last Close

2.04

21/11 21:00

Market Cap

95.39M

Beta: -

Volume Today

312.81K

Avg: -

Preview